Takefumi Komiya

Oncology
11050 Parkview Circle Dr
Fort Wayne, IN 46845

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 62 publications

ASO Visual Abstract: Efficacy of Adjuvant Chemoimmunotherapy Versus Chemotherapy and the Impact of Lymph Node Dissection on Survival.

ASO Visual Abstract: Efficacy of Adjuvant Chemoimmunotherapy Versus Chemotherapy and the Impact of Lymph Node Dissection on Survival.

Journal: Annals of surgical oncology
Published: June 03, 2026

ASO Author Reflections: Does Lymph Node Dissection Impair the Efficacy of Adjuvant Immune Checkpoint Inhibitors?

ASO Author Reflections: Does Lymph Node Dissection Impair the Efficacy of Adjuvant Immune Checkpoint Inhibitors?

Journal: Annals of surgical oncology
Published: May 19, 2026

Correction: Evaluating the role of consolidative chest radiotherapy after chemo‑immunotherapy in extensive‑stage small cell lung cancer: a retrospective study.

Correction: Evaluating the role of consolidative chest radiotherapy after chemo‑immunotherapy in extensive‑stage small cell lung cancer: a retrospective study.

Journal: Discover oncology
Published: April 16, 2026

Incidence and Prognostic Value of TP53, STK11, and KEAP1 Mutations Between De Novo Versus Recurrent Actionable Mutation-Negative Non-Small Cell Lung Cancer: A Single-Center Retrospective Study.

Incidence and Prognostic Value of TP53, STK11, and KEAP1 Mutations Between De Novo Versus Recurrent Actionable Mutation-Negative Non-Small Cell Lung Cancer: A Single-Center Retrospective Study.

Journal: World journal of oncology
Published: March 07, 2026

M1C is a druggable target for NSCLC KRAS G12C mutant tumors resistant to KRAS inhibitors.

M1C is a druggable target for NSCLC KRAS G12C mutant tumors resistant to KRAS inhibitors.

Journal: Oncogene
Published: March 05, 2026

Efficacy of Adjuvant Chemoimmunotherapy versus Chemotherapy and the Impact of Lymph Node Dissection on Survival.

Efficacy of Adjuvant Chemoimmunotherapy versus Chemotherapy and the Impact of Lymph Node Dissection on Survival.

Journal: Annals of surgical oncology
Published: November 12, 2025

Novel MAML2 Fusions in Human Malignancy.

Novel MAML2 Fusions in Human Malignancy.

Journal: Cancers
Published: August 19, 2025

ASO Author Reflections: Examining the Outcomes of Adding Immunotherapy to Adjuvant Chemoradiation in Pathologic Stage II-IIIB Non-Small Cell Lung Cancer.

ASO Author Reflections: Examining the Outcomes of Adding Immunotherapy to Adjuvant Chemoradiation in Pathologic Stage II-IIIB Non-Small Cell Lung Cancer.

Journal: Annals of surgical oncology
Published: June 30, 2025

Lack of Survival Benefit with Immunotherapy in Combination with Adjuvant Chemoradiation in Pathologic Stage II-IIIB Non-small Cell Lung Cancer.

Lack of Survival Benefit with Immunotherapy in Combination with Adjuvant Chemoradiation in Pathologic Stage II-IIIB Non-small Cell Lung Cancer.

Journal: Annals of surgical oncology
Published: March 24, 2025

Narrative review of the prognostic significance of primary tumor size in thymic epithelial tumor.

Narrative review of the prognostic significance of primary tumor size in thymic epithelial tumor.

Journal: Mediastinum (Hong Kong, China)
Published: January 31, 2025

Evaluating the role of consolidative chest radiotherapy after chemo-immunotherapy in extensive-stage small cell lung cancer: a retrospective study.

Evaluating the role of consolidative chest radiotherapy after chemo-immunotherapy in extensive-stage small cell lung cancer: a retrospective study.

Journal: Discover oncology
Published: January 01, 2025

Evaluating the role of consolidative chest radiotherapy after chemo-immunotherapy in extensive-stage small cell lung cancer: a retrospective study.

Evaluating the role of consolidative chest radiotherapy after chemo-immunotherapy in extensive-stage small cell lung cancer: a retrospective study.

Journal: Discover oncology
Published: January 01, 2025
Showing 1-12 of 62

Last Updated: 09/26/2026